BRICS AIDS medicines and antiretroviral therapy protection strategy and implications for China / 中国卫生政策研究

ABSTRACT

BRICS has been dealing with the problem of increase in the number of the patients who require an-tiretroviral therapy and this therapy’s price-rise by promoting medicine to domestic production and reducing the impor-ted drug price. This paper reviewed the situation of BRICS HIV epidemic and prevention, anti-retroviral therapy drugs production and supply, drug security policy and strategy, and the following seven recommendations are straight forwarded to China based on the BRICS AIDS antiretroviral treatment coverage strategic comparison(1) The estab-lishment of an ARV drugs co-ordination mechanism;(2) The reduction of the drug patent licenses while increasing the domestic generic drugs possibility;(3)Negotiations with the original research process of domestic pharmaceutical enterprises to obtain a voluntary license or speed up the technology transfer;(4) The use of antitrust laws to promote access to medicines for a voluntary license pharmacy localization; ( 5 ) If necessary, starting the compulsory medi-cines licensing to achieve localization;(6) Reducing the drug prices by bargain and negotiation;and (7) Strengthe-ning NGO built-in capacity.